Literature DB >> 21208059

Improving effects of long-term growth hormone treatment on monoaminergic neurotransmission and related behavioral tests in aged rats.

Susana Esteban1, Celia Garau, Sara Aparicio, David Moranta, Pere Barceló, Margarita Ramis, Jesús A F Tresguerres, Rubén Rial.   

Abstract

An age-related decline in cognitive functions and physical performance has been associated with reductions in growth hormone (GH) secretion and brain neurotransmitter function. In vivo experiments were performed to study the long-term effects of exogenously administered GH on the central monoaminergic neurotransmitters serotonin, dopamine, and noradrenaline and behavioral tests in old Wistar rats. The accumulation of 5-hydroxytryptophan (5-HTP) and L-3,4-dihydroxyphenylalanine (DOPA) after decarboxylase inhibition was used as a measure of the rate of tryptophan and tyrosine hydroxylation in vivo. Also, the content of the neurotransmitters serotonin, dopamine, and noradrenaline and some metabolites was measured by high-pressure liquid chromatography (HPLC) in the hippocampus and striatum, brain regions involved in adult memory processing and motor coordination. The age-related decline observed in all the neurochemical parameters in control rats was significantly reversed after repeated subcutaneous administration of GH (2 mg/kg per day, 4 weeks). Thus, GH treatment exerted a long-term effect on serotonin, dopamine, and noradrenaline neurotransmission by enhancing neurotransmitter synthesis and metabolism in aged rats. The results obtained after examining working memory tasks in the eight-radial maze and motor ability in the Rotarod treadmill in aged rats were consistent with these neurochemical data; both tests were significantly improved after chronic GH treatment. Overall, these in vivo findings suggest that the positive effects induced by GH on serotonin, dopamine, and noradrenaline neurotransmitters might explain, at least in part, the effects of chronic GH treatment in improving cognitive and motor ability in aged rats, and could aid in preventing or delaying deficits in monoamines associated with learning or motor disabilities.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21208059     DOI: 10.1089/rej.2010.1053

Source DB:  PubMed          Journal:  Rejuvenation Res        ISSN: 1549-1684            Impact factor:   4.663


  6 in total

1.  Chronic Silymarin, Quercetin and Naringenin Treatments Increase Monoamines Synthesis and Hippocampal Sirt1 Levels Improving Cognition in Aged Rats.

Authors:  F Sarubbo; M R Ramis; C Kienzer; S Aparicio; S Esteban; A Miralles; D Moranta
Journal:  J Neuroimmune Pharmacol       Date:  2017-08-14       Impact factor: 4.147

2.  Improving effect of chronic resveratrol treatment on central monoamine synthesis and cognition in aged rats.

Authors:  F Sarubbo; M R Ramis; S Aparicio; L Ruiz; S Esteban; A Miralles; D Moranta
Journal:  Age (Dordr)       Date:  2015-04-22

3.  Growth hormone and melatonin prevent age-related alteration in apoptosis processes in the dentate gyrus of male rats.

Authors:  R A Kireev; E Vara; J A F Tresguerres
Journal:  Biogerontology       Date:  2013-07-13       Impact factor: 4.277

4.  Chronic Polyphenon-60 or Catechin Treatments Increase Brain Monoamines Syntheses and Hippocampal SIRT1 Levels Improving Cognition in Aged Rats.

Authors:  Margarita R Ramis; Fiorella Sarubbo; Silvia Tejada; Manuel Jiménez; Susana Esteban; Antoni Miralles; David Moranta
Journal:  Nutrients       Date:  2020-01-26       Impact factor: 5.717

5.  Caloric restriction modulates the monoaminergic system and metabolic hormones in aged rats.

Authors:  Marta Portero-Tresserra; D Rojic-Becker; C Vega-Carbajal; G Guillazo-Blanch; A Vale-Martínez; M Martí-Nicolovius
Journal:  Sci Rep       Date:  2020-11-09       Impact factor: 4.379

Review 6.  Effects of Resveratrol and other Polyphenols on Sirt1: Relevance to Brain Function During Aging.

Authors:  F Sarubbo; S Esteban; A Miralles; D Moranta
Journal:  Curr Neuropharmacol       Date:  2018-01-30       Impact factor: 7.363

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.